Immune checkpoints are regulators of immune activation by regulating the antigen recognition of T cell receptor (TCR) in the process of immune response. They play a key role in maintaining immune homeostasis and preventing autoimmunity.
Based on the different role for immune activation, immune checkpoints are divided into two types: co-stimulatory immune checkpoints and co-inhibitory immune checkpoints.
Co-stimulatory immune checkpoints refer to one kind of immune checkpoint which can stimulate immune progress, such as CD28, ICOS, and CD137.
On the contract, co-inhibitory immune checkpoints play a negative role to immune progress. They inhibit immune progress, such as PD1, CTLA-4, and VISTA.
In cancer, immune checkpoint mechanisms are often activated to suppress the nascent anti-tumor immune response. This has led to the development of several checkpoint inhibitor antibody drugs that are currently being tested in clinical trials or have been approved for a number of cancers.
Recently, the R&D team from CUSABIO has developed various recombinant proteins of immune checkpoints for the researchers in this filed.
These recombinant immune checkpoint proteins cover multiple species and labels, and their biological activities are strictly analyzed and verified before shipping. In addition, we provide protein customization service. If you can't find the protein you need, please contact us for custom service.
What are Immune Checkpoint Proteins?
What is An Immune Checkpoint Inhibitor?